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INTRODUCTION
The metabolism of tumor cells is different from that of nor-
mal cells in that tumor cells obtain energy from aerobic gly-
colysis instead of the tricarboxylic acid cycle (TCA cycle). This 
alternative form of metabolism is referred to as Warburg effect 
[1]. Because of inadequate oxygen supply due to limited blood 
flow, rapidly proliferating tumor cells encounter an oxygen-
deficient environment. As an adaptive response to this condi-
tion, the tumor cells use aerobic glycolysis, which consumes 
less oxygen than the TCA cycle [2]. The proteins involved in 
aerobic glycolysis include glucose transporter 1 (Glut-1), an 
important channel mediating glucose influx into the tumor 
cell; carbonic anhydrase IX (CAIX), a pH regulating enzyme 
that is up-regulated in association with glycolysis-related aci-
dosis; and monocarboxylate transporter 4 (MCT4), a trans-
porter mediating extracellular efflux of lactate produced dur-
ing aerobic glycolysis [3,4]. Expression of these metabolism-
related proteins is associated with clinicopathologic parame-
ters in many tumors. Overexpression of Glut-1 was reported 
to be associated with high-grade and poorly differentiated 
tumors, invasiveness and distant metastasis [5-7]. In addition, 
overexpression of CAIX was reported to be associated with 
high-grade tumors and poor prognosis [8,9]. It can therefore 
be inferred that the higher the metabolic rate of a tumor has, 
the more aggressive behavior it shows.
Mucinous carcinoma is a rare variant of invasive breast can-
cer, which constitutes about 2% of all breast cancers and is 
characterized by abundant mucin production. Carcinomas 
that are comprised of at least 90% mucus are defined as muci-
nous carcinoma [10]. Mucinous carcinoma usually occurs in 
postmenopausal women and is associated with a lower inci-
dence of nodal metastasis, high expression of estrogen recep-
tor (ER) and progesterone receptor (PR). It is known to have a 
favorable prognosis [11,12]. Some authors have suggested that 
mucinous carcinoma be classified into two groups according 
to the histological characteristics. They are type A (paucicellu-
lar), the classical variant with a large amount of extracellular 
mucin and type B (hypercellular), the hypercellular variant 
with less mucin and often neuroendocrine differentiation [13].
While expression of metabolism-related proteins in typical 
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breast carcinoma has been previously studied, the expression 
of these proteins in mucinous carcinoma, a rare variant of 
breast carcinoma, has not yet been studied. The aim of this 
study was to assess the expression of metabolism-related pro-
teins including Glut-1, CAIX and MCT4 in breast mucinous 
carcinoma and to evaluate the implications of the results.
METHODS
Patient selection and clinicopathologic analysis
A total of 59 patients who were diagnosed with mucinous 
carcinoma and underwent surgical excision at Severance Hos-
pital from January 1996 to December 2009 were included in 
this study. Cases of mixed mucinous carcinoma and invasive 
ductal carcinoma were excluded. Mucinous carcinoma was 
diagnosed only when at least 90% tumor produce extracellular 
mucin [10]. This study was approved by the Institutional Re-
view Board of Yonsei University Severance Hospital. All cases 
included in the study were retrospectively reviewed indepen-
dently by experienced breast pathologists (JS Koo and WH 
Jung). Histologic parameters were evaluated from hematoxy-
lin and eosin (H&E)-stained slides. The histological grade was 
assessed using the Nottingham grading system [14], and nu-
clear grade was evaluated according to the modified Black’s 
nuclear grade (1= low grade, 2= intermediate grade, and 
3=high grade). Mucinous carcinoma was classified into type 
A and B according to the following criteria described by Ca-
pella et al. [13]: type A (paucicellular), the classical variant 
with a large amount of extracellular mucin; and type B (hyper-
cellular), hypercellular variant with less mucin and often neu-
roendocrine differentiation. Clinicopathologic parameters 
evaluated in each tumor included patient age at initial diagno-
sis, sex, lymph node metastasis, tumor recurrence, distant me-
tastasis and patient survival.
Ethics approval
The materials are human breast cancer tissue samples, 
which are products of surgical treatment. In addition, our 
study contains no private information on patients. Therefore, 
our study has no problems in causing any ethical issue or en-
croachment of human rights (IRB approval number: 4-2012-
0606).
Tissue microarray
On H&E-stained tumor slides, a representative area was se-
lected and a corresponding spot was marked on the surface of 
the paraffin block. Using a biopsy needle, the selected area 
was punched out and a 3-mm tissue core was placed into a 
6×5 recipient block. Tissue from the invasive tumor was ex-
tracted. More than two tissue cores were extracted to mini-
mize extraction bias. Each tissue core was assigned a unique 
tissue microarray location number that was linked to a data-
base containing other clinicopathologic data. 
Immunohistochemistry
All immunohistochemical staining was performed on the 
formalin-fixed, paraffin-embedded tissue sections. Briefly, 
5-μm-thick sections were obtained with a microtome, trans-
ferred onto adhesive slides, and dried at 62°C for 30 minutes. 
After incubation with primary antibodies for Glut-1 (SPM498, 
1:200; Abcam, Cambridge, UK), CAIX (polyclonal, 1:100; Ab-
cam), and MCT4 (polyclonal, 1:100; Santa Cruz Biotechnolo-
gy, Santa Cruz, USA), immunodetection was performed with 
biotinylated anti-mouse immunoglobulin, followed by peroxi-
dase-labeled streptavidin using a labeled streptavidin biotin kit 
(DAKO, Carpinteria, USA) with 3,3᾿-diaminobenzidine chro-
mogen as the substrate. The primary antibody incubation step 
was omitted in the negative control. Slides were counterstained 
with Harris hematoxylin. 
Interpretation of immunohistochemical staining
All immunohistochemical markers were assessed by light 
microscopy. Pathologic parameters such as ER, PR, and HER2 
status were obtained from patients’ pathology reports. A cut-
off value of 1% or more of positively stained nuclei was used 
to define ER and PR positivity [15]. HER2 staining was ana-
lyzed according to the American Society of Clinical Oncology 
(ASCO)/College of American Pathologists (CAP) guidelines 
using the following categories: 0=no immuno staining; 1+ 
=weak, incomplete membranous staining, less than 10% of 
tumor cells; 2+ =complete membranous staining, either uni-
form or weak in at least 10% of tumor cells; and 3+ =uniform 
intense membranous staining in at least 30% of tumor cells. 
HER2 immunostaining was considered positive when strong 
(3+) membranous staining was observed, whereas cases grad-
ed as 0 to 1+ were regarded as negative [16]. The cases show-
ing 2+ HER2 expression were evaluated for HER2 amplifica-
tion by fluorescent in situ hybridization (FISH).
FISH analysis
Before FISH analysis, invasive tumors were examined on 
H&E-stained slides. FISH was subsequently performed on the 
tested tumor using a PathVysion HER2 DNA Probe Kit (Vy-
sis, Downers Grove, USA) according to the manufacturer’s in-
structions. The HER2 gene copy number on the slides was 
evaluated using an epifluorescence microscope (Olympus, 
Tokyo, Japan). At least 60 tumor cell nuclei in three separate 
regions were investigated for HER2 and chromosome 17 sig-
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nals. HER2 gene amplification was determined according to 
the ASCO/CAP guidelines [16]. An absolute HER2 gene copy 
number lower than 4 or a HER2 gene/chromosome 17 copy 
number ratio (HER2/Chr17 ratio) less than 1.8 was consid-
ered HER2-negative. An absolute HER2 copy number be-
tween 4 and 6 or a HER2/Chr17 ratio between 1.8 and 2.2 was 
considered HER2 equivocal. An absolute HER2 copy number 
greater than 6 or a HER2/Chr17 ratio higher than 2.2 was 
considered HER2-positive.
Statistical analysis
Data were processed using SPSS for Windows, version 12.0 
(SPSS Inc., Chicago, USA). Student’s t-test and Fisher’s exact 
test were used to examine any differences in continuous and 
categorical variables, respectively. Pearson’s correlation analy-
sis was performed to assess the relationships among Glut-1, 
CAIX, and MCT4 expression. Significance was assumed 
when p<0.05. Kaplan-Meier survival curves and log-rank 
statistics were employed to evaluate time to tumor metastasis 
and survival. Multivariate regression analysis was performed 
using the Cox proportional hazards model. 
RESULTS
Patient characteristics
The clinicopathologic characteristics of the patients in this 
study are shown in Table 1. Among the 59 patients, 35 (59.3%) 
had type A mucinous carcinoma and 24 (40.7%) had type B 
mucinous carcinoma. There was no difference in clinico-
pathologic parameters between the two groups, except that 
type B mucinous carcinoma had a higher histological grade 
than type A (p=0.040). Tumor recurrence occurred in only 
one patient (1.7%) and no patient died of breast cancer. 
Correlation between metabolism-related protein expression 
and clinicopathologic factors
The correlation between the expression of metabolism- 
related proteins and clinicopathologic factors is shown in Table 
2 and Figure 1. Stromal expression of MCT4 was significantly 
associated with high histologic grade (p=0.022) and type B 
mucinous carcinoma (p=0.016). Although not significant, 
CAIX expression tended to be associated with type B mucin-
ous carcinoma (p=0.109) and Glut-1 and MCT-4 expression 
Figure 1. Immunohistochemical staining of monocarboxylate transport-
er 4 (MCT4), glucose transporter 1 (Glut-1), and carbonic anhydrase IX 
(CAIX) according to the subtype of mucinous carcinoma. Type B muci-
nous carcinoma shows high expression of MCT4 in the tumor stroma, 
but type A mucinous carcinoma demonstrates no expression of MCT4 
in the tumor stroma. 
MCT4=monocarboxylate transporter 4; Glut-1=glucose transporter 1;
CAIX=carbonic anhydrase IX.
H&E
MCT4
Glut-1
CAIX
Type A                         Type B
Table 1. Patient characteristics
Parameter
Total (n=59) 
No. (%)
Type A (n=35) 
No. (%)
Type B (n=24) 
No. (%)
p-value
Age (yr)* 50.8±13.6 49.0±12.8 49.0±12.8 0.226
Tumor size (cm)* 2.1±0.8 2.2±0.9 2.2±0.9 0.222
Nuclear grade 0.248
    1 44 (74.6) 28 (80.0) 28 (80.0)
    2 15 (25.4) 7 (20.0) 7 (20.0)
Histologic grade 0.040
    I 47 (79.7) 31 (88.6) 31 (88.6)
    II 12 (20.3) 4 (11.4) 4 (11.4)
ER 0.206
    Negative 6 (10.2) 5 (14.3) 5 (14.3)
    Positive 53 (89.8) 30 (85.7) 30 (85.7)
PR 0.291
    Negative 14 (23.7) 10 (28.6) 10 (28.6)
    Positive 45 (76.3) 25 (71.4) 25 (71.4)
HER2 0.141
    Negative 56 (94.9) 32 (91.4) 32 (91.4)
    Positive 3 (5.1) 3 (8.6) 3 (8.6)
LN metastasis 0.092
    Negative 48 (81.4) 26 (74.3) 26 (74.3)
    Positive 11 (18.6) 9 (25.7) 9 (25.7)
ER=estrogen receptor; PR=progesterone receptor; LN= lymph node.
*Mean±SD.
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tended to be associated with lymph node metastasis (p=0.129 
and 0.109, respectively).
Correlation among the metabolism-related proteins
There were significant positive correlations among Glut-1, 
CAIX and tumoral MCT4 expression (p<0.05). However, 
there was no correlation between stromal MCT4 expression 
and other parameters (Table 3).
DISCUSSION
In this study, we assessed the expression of metabolism-re-
lated proteins including Glut-1, CAIX and MCT4 in mucinous 
carcinoma of the breast and evaluated the implications of the 
results. This study demonstrated that Glut-1 was expressed in 
27% of mucinous carcinoma tissues. Previous studies reported 
that Glut-1 was expressed in 40% to 50% of invasive ductal 
carcinoma (IDC), not otherwise specified (NOS) [5,9,17]. In 
comparison with previous studies, our results show that Glut-
1 expression is lower in mucinous carcinoma tissues than in 
IDC, NOS. Previous studies reported that Glut-1 expression 
is associated with high histologic grade, high proliferative ac-
tivity, poor differenti ation, ER negativity, PR negativity and a 
basal-like subtype [9,18,19]. Mucinous carcinoma is known 
to have low histologic grade, low proliferative activity, high 
ER positivity and PR positivity. Therefore, it can be expected 
that mucinous carcinoma tissues would show low expression 
of Glut-1, and our data confirmed this hypothesis. It can 
therefore be inferred that mucinous carcinoma has a low rate 
of aerobic glycolysis.
This study demonstrated that 34% of mucinous carcinoma 
tissues express CAIX. In comparison with previous studies 
which reported that 13% to 18% of IDC, NOS tissues express 
CAIX, we found that CAIX expression in mucinous carcino-
Table 2. Correlation between the expression of metabolism-related proteins and clinicopathologic factors
Parameter
Glut-1 CAIX MCT4 in the tumor MCT4 in the stroma
Negative
(n=43)
No. (%)
Positive
(n=16)
No. (%)
p-value
Negative
(n=39)
No. (%)
Positive
(n=20)
No. (%)
p-value
Negative
(n=39)
No. (%)
Positive
(n=20)
No. (%)
p-value
Negative
(n=48)
No. (%)
Positive
(n=11)
No. (%)
p-value
Age (yr)* 51.1±13.8 50.0±13.4 0.774 51.0±15.0 50.5±10.7 0.890 51.5±14.5 49.4±11.8 0.564 49.3±13.1 57.5±14.2 0.071
Tumor size (cm)* 2.2±0.8 2.0±0.7 0.435 2.1±0.9 2.1±0.6 0.889 2.2±0.8 1.9±0.6 0.217 2.1±0.8 2.3±0.5 0.586
Nuclear grade 0.531 0.493 0.957 0.356
  1 33 (76.7) 11 (68.8) 28 (71.8) 16 (80.0) 29 (74.4) 15 (75.0) 37 (77.1) 7 (63.6)
  2 10 (23.3) 5 (31.2) 11 (28.2) 4 (20.0) 10 (25.6) 5 (25.0) 11 (22.9) 4 (36.4)
Histologic grade 0.587 0.963 0.524 0.022
  1 35 (81.4) 12 (75.0) 31 (79.5) 16 (80.0) 32 (82.1) 15 (75.0) 41 (85.4) 6 (54.5)
  2 8 (18.6) 4 (25.0) 8 (20.5) 4 (20.0) 7 (17.9) 5 (25.0) 7 (14.6) 5 (45.5)
Histologic type 0.762 0.109 0.525 0.016
  Type A 25 (58.1) 10 (62.5) 26 (66.7) 9 (45.0) 22 (56.4) 13 (65.0) 32 (66.7) 3 (27.3)
  Type B 18 (41.9) 6 (37.5) 13 (33.3) 11 (55.0) 17 (43.6) 7 (35.0) 16 (33.3) 8 (72.7)
Estrogen receptor 0.543 0.975 0.347 0.896
  Negative 5 (11.6) 1 (6.3) 4 (10.3) 2 (10.0) 5 (12.8) 1 (5.0) 5 (10.4) 1 (9.1)
  Positive 38 (88.4) 15 (93.8) 35 (89.7) 18 (90.0) 34 (87.2) 19 (95.0) 43 (89.6) 10 (90.9)
Progesterone receptor 0.889 0.145 0.417 0.632
  Negative 10 (23.3) 4 (25.0) 7 (17.9) 7 (35.0) 8 (20.5) 6 (30.0) 12 (25.0) 2 (18.2)
  Positive 33 (76.7) 12 (75.0) 32 (82.1) 13 (65.0) 31 (79.5) 14 (70.0) 36 (75.0) 9 (81.8)
HER2 0.804 0.218 0.218 0.503
  Negative 41 (95.3) 15 (93.8) 38 (97.4) 18 (90.0) 38 (97.4) 18 (90.0) 46 (95.8) 10 (90.9)
  Positive 2 (4.7) 1 (6.3) 1 (2.6) 2 (20.0) 1 (2.6) 2 (10.0) 2 (4.2) 1 (9.1)
Lymph node metastasis 0.129 0.369 0.109 0.965
  Negative 37 (86.0) 11 (68.8) 33 (84.6) 15 (75.0) 34 (87.2) 14 (70.0) 39 (81.3) 9 (81.8)
  Positive 6 (14.0) 5 (31.2) 6 (15.4) 5 (25.0) 5 (12.8) 6 (30.0) 9 (18.8) 2 (18.2)
Glut-1=glucose transporter 1; CAIX=carbonic anhydrase IX; MCT4=monocarboxylate transporter 4.
* Mean±SD.
Table 3. Correlations among the metabolism-related proteins
Glut-1 CAIX
MCT4
(tumor)
MCT4
(stroma)
Glut-1 Coefficient 0.449 0.449 0.100
p-value <0.001 <0.001 0.453
CAIX Coefficient 0.319 0.209
p-value 0.014 0.112
MCT4
(tumor)
Coefficient
p-value
0.209
0.112
Glut-1=glucose transporter 1; CAIX=carbonic anhydrase IX; MCT4=  
monocarboxylate transporter 4.
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ma tissues is higher than in IDC, NOS [8,9,18,20,21]. It was 
reported that CAIX expression in breast cancer is associated 
with high histologic grade, ER negativity, PR negativity, and 
basal-like breast cancer [8,9,18,20,21]. From these reports it 
can be expected that CAIX expression would be low in muci-
nous carcinoma tissues. However, contrary to expectations, 
CAIX expression was higher in mucinous carcinoma tissues 
than in IDC, NOS. However, this comparison is between dif-
ferent studies that used different study groups and research 
methodologies, and thus it is not statistically significant. 
The higher expression of CAIX in mucinous carcinoma 
compared to IDC can be attributed to histological features. 
Mucinous carcinoma tissues have a characteristic histology 
where nests of cancer cells are floating on the mucin pool, 
consequently the cancer cells are separated from the stroma 
[11]. For this reason, there is a high probability that tumor 
cells are far away from the blood vessels and are subjected to 
tissue hypoxia. Because a previous study reported that CAIX 
is an indicator of tissue hypoxia [22], CAIX is expected to be 
highly expressed in mucinous carcinoma tissues.
This study demonstrated that stromal expression of MCT4 
is significantly associated with high histologic grade (p=0.022) 
and type B mucinous carcinoma (p=0.016). MCT4 is ex-
pressed in glycolytic cells and mediates extracellular efflux of 
lactic acid produced during glycolysis [23]. Therefore, there 
are close correlations between Glut-1, which mediates glucose 
influx during aerobic glycolysis, CAIX, which is up-regulated 
in association with glycolysis-related acidosis, and MCT-4, 
which mediates efflux of lactate produced during aerobic gly-
colysis. This study showed that there are significant positive 
correlations between the expression of Glut-1, CAIX and tu-
moral expression of MCT4 (p<0.05). However, there was no 
correlation between stromal MCT4 expression and other pa-
rameters.
Most previous studies have focused on the tumoral expres-
sion of MCT4. However, this study showed that stromal ex-
pression of MCT4 was associated with pathological factors. A 
previous study reported that MCT4 is an oxidative stress indi-
cator of cancer-associated fibroblasts in breast cancer [24]. 
Therefore, MCT4 is expressed in the stroma of the tumor, and 
high stromal expression of MCT4 is associated with decreased 
overall survival [25]. Stromal expression of MCT4 in breast 
cancer represents the reverse Warburg effect, which refers to 
the fact that peritumoral stromal cells undergo aerobic glycol-
ysis, thereby producing lactic acid, which is released from the 
stromal cells with the help of MCT4 and subsequently used as 
a substrate for oxidative phosphorylation by adjacent cancer 
cells [24].
However, stromal expression of Glut-1 and CAIX was not 
observed in this study. Therefore, it is inappropriate to regard 
the stromal expression of MCT4 in mucinous carcinoma tis-
sues as the reverse Warburg effect. Furthermore, prognostic 
analysis was impossible due to the excellent prognosis of mu-
cinous carcinoma (tumor recurrence in only one patient 
[1.7%] and no deaths from breast cancer).
Stromal expression of MCT4 was higher in type B muci-
nous carcinoma than in type A. There are histological differ-
ences between type A and B mucinous carcinoma; type A is a 
paucicellular tumor with an abundant mucin pool and a solid, 
trabecular growth pattern, while type B is a hypercellular tu-
mor with neuroendocrine differentiation [13]. In addition to 
histological differences, type A and B mucinous carcinoma 
were reported to show different patterns of MUC protein ex-
pression. Type A showed luminal/apical expression of MUC1 
and MUC2, while type B showed membrano-cytoplasmic ex-
pression of MUC1 and MUC2. Type A was negative for 
MUC5B, while type B showed membrano-cytoplasmic ex-
pression of MUC5B [26]. Such differences in the intrinsic 
characteristics of type A and B mucinous carcinoma may con-
tribute to the difference in tumor microenvironments, which 
would create distinct differences in MCT4 stromal expression. 
Further studies of the difference in tumor microenvironments 
between type A and B mucinous carcinoma are needed. 
In this study, we investigated the expression of metabolism-
related proteins including Glut-1, CAIX, and MCT4 in breast 
mucinous carcinoma. In conclusion, stromal expression of 
MCT4 was higher in type B mucinous carcinoma than in type 
A, which reflected a difference in the tumor microenviron-
ment.
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